Ataxxa 200 mg/40 mg spot-on solution for dogs up to 4 kg

Authorised

- Permethrin
- Imidacloprid

Product identification

Medicine name:
Ataxxa 200 mg/40 mg spot-on solution for dogs up to 4 kg

Active substance:
Permethrin

Imidacloprid

Target species:
Dog

Route of administration:
Spot-on use

Product details

Active substance and strength:
Permethrin
200.00 milligram(s) / 1.00 Pipette

Imidacloprid

40.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:
Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP53AC54

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria

Package description:
Available only in German
Available only in German
Available only in German
Available only in German
Available only in German
White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.1 ml pipette containing 0.4 ml of solution. Box containing 1 pipette.
White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.1 ml pipette containing 0.4 ml of solution. Box containing 3 pipettes.
White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.1 ml pipette containing 0.4 ml of solution. Box containing 4 pipettes.
White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.1 ml pipette containing 0.4 ml of solution. Box containing 6 pipettes.
White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.1 ml pipette containing 0.4 ml of solution. Box containing 10 pipettes.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
20/10/2015

Manufacturing sites for batch release:
KRKA tovarna zdravil d.d. Novo mesto
TAD Pharma GmbH

Responsible authority:
Austrian Agency For Health And Food Safety

Authorisation number:
836574

Date of authorisation status change:
20/10/2015

Reference member state:
Ireland

Procedure number:
IE/V/0439/001

Concerned member states:
Austria Belgium Bulgaria Croatia Czechia Estonia France Germany Hungary Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 30/06/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.